Federated Hermes’s Clearside Biomedical CLSD Stock Holding History

Federated Hermes’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5	Closed	-$1K	–	2180
2022 Q3	$1K	Buy	+5	New	+$110	﹤0.01%	2019
2021 Q4	–	Sell	-4	Closed	-$1K	–	2215
2021 Q3	$1K	Buy	+4	New	+$353	﹤0.01%	2125
2021 Q2	–	Sell	-54	Closed	-$2K	–	2224
2021 Q1	$2K	Buy	+54	New	+$2.71K	﹤0.01%	2117

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Federated Hermes's CLSD Position: Q4 2022 in Review

Federated Hermes sold out of Clearside Biomedical (CLSD) in Q4 2022, closing a stake of 5 shares — an estimated $1K sold.

Federated Hermes first reported a position in CLSD in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q1 2021. 53 funds tracked by Wall St. Rank hold CLSD as of Q4 2022.

Federated Hermes reported no remaining Clearside Biomedical position as of Q4 2022 after selling out during the quarter.
Federated Hermes sold 5 Clearside Biomedical shares in Q4 2022, an estimated $1K.
Federated Hermes first reported a position in Clearside Biomedical in Q1 2021 and held it in 3 quarters.
Federated Hermes's Clearside Biomedical position peaked at $2K in Q1 2021.
53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2022.

Based on Federated Hermes's 13F filing for Q4 2022, filed 13 Feb 2023.